Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma

Leuk Lymphoma. 2012 Mar;53(3):506-7. doi: 10.3109/10428194.2011.614706. Epub 2011 Oct 10.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Brentuximab Vedotin
  • Carmustine / administration & dosage
  • Clinical Trials, Phase I as Topic
  • Cyclophosphamide / administration & dosage
  • Cytarabine / administration & dosage
  • Doxorubicin / administration & dosage
  • Etoposide / administration & dosage
  • Humans
  • Immunoconjugates / administration & dosage
  • Immunoconjugates / therapeutic use*
  • Lymphoma, Large-Cell, Anaplastic / drug therapy*
  • Lymphoma, Large-Cell, Anaplastic / surgery
  • Maintenance Chemotherapy
  • Male
  • Melphalan / administration & dosage
  • Prednisone / administration & dosage
  • Remission Induction
  • Stem Cell Transplantation
  • Transplantation, Autologous
  • Vincristine / administration & dosage

Substances

  • Immunoconjugates
  • Cytarabine
  • Vincristine
  • Etoposide
  • Brentuximab Vedotin
  • Doxorubicin
  • Cyclophosphamide
  • Melphalan
  • Carmustine
  • Prednisone

Supplementary concepts

  • BEAM regimen
  • CHOP protocol